Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Denali Therapeutics (DNLI) has 6 years of Other Accumulated Expenses data on file, last reported at $4.4 million in Q4 2022.

• Other Accumulated Expenses for Q4 2022 came in at $4.4 million, down 91.75% year-over-year; the trailing twelve-month figure through Dec 2022 was $4.4 million (down 91.75% YoY), and the FY2022 annual result was $4.4 million, down 91.75% from the prior year.
• Other Accumulated Expenses fell to $4.4 million in Q4 2022 per DNLI's latest filing, from $53.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $53.2 million in Q4 2021 and troughed at $47000.0 in Q2 2018.
• A 5-year average of $14.1 million and a median of $3.5 million in 2019 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2018 and 2022: Other Accumulated Expenses soared 30801.59% in 2018, then slumped 91.75% in 2022.
• A 5-year view of Other Accumulated Expenses shows it stood at $19.5 million in 2018, then climbed by 23.36% to $24.0 million in 2019, then jumped by 96.31% to $47.1 million in 2020, then climbed by 12.77% to $53.2 million in 2021, then tumbled by 91.75% to $4.4 million in 2022.
• Business Quant data shows DNLI's Other Accumulated Expenses at $4.4 million in Q4 2022, $53.2 million in Q4 2021, and $47.1 million in Q4 2020.